The Erenna™ Technology Access Program (ETAP)
The Erenna Technology Access Program (ETAP) is a collaborative partnership designed to provide semi-exclusive access to Singulex’s technology, know-how and capabilities that support biomarker-based development projects for our partners.
The ETAP offers:
- State of the art Erenna Immunoassay System.
- Ultrasensitive Erenna immunoassay technology.
- Flexible and rapid immunoassay development services.
- Custom assays and access to Singulex commercial assay kits.
- Sample analysis service in a GLP lab setting.
- World-class technical support for assays and system.
- Total instrument service coverage.
Singulex is absolutely committed to you— we will meet or exceed your expectations for assay performance and technical support.
Service is essential to the ETAP partnership, and quality
service begins with a team you can trust. Each member
of our technical team has extensive experience using our
technology and a proven track record of at least 3 years
supporting ETAP partners. We develop a relationship with
our partners for mutual success. Our technical team is
ready to support you through:
- Commitment—Our assay development projects are managed by a lead scientist from start to finish.
- Dedication—Technical support representatives maintain no more than three partners at any time, ensuring that you get first-class, personalized service.
- Just-in-Time Results—Singulex delivers assay testing results in as little as one week.
- Customization—We offer proprietary assay development, tailored to meet your needs.
- Integration—We work closely with you to seamlessly integrate our assays into your laboratory workflow.
We develop each of our immunoassays specifically to be
run on the Erenna System. New assay development projects
are taken from concept to characterized or validated
assay in 6–12 weeks. Our assays are thoroughly tested
and pass stringent QA requirements before we use your
precious specimens, ensuring that when we test your
sample, we get it right the first time.
- Quick prototyping of immunoassays to identify antibody candidates and appropriate standards.
- Assay performance optimization to achieve a low limit of quanitification and maintain high precision and linearity.
- Characterization of the resulting immunoassay against a set of analytical performance specifications.
- Assay validation using partner-specific criteria and delivery of detailed validation reports.
- Sample analysis services based upon validated assays, performed in Singulex’s GLP lab with rapid turnaround.
An ETAP partnership with Singulex can mean faster and
more effective development cycles through more efficient
use of biomarker endpoints, and because Singulex optimizes
your biomarker assays, your time can be focused on
product development. Our partners achieve success because
access to the cutting-edge Erenna Immunoassay
System allows:
- Benchmarking of baseline biomarker levels in healthy individuals by precise measurement of minute biomarker concentrations.
- Differentiation between diseased and healthy states in readily accessible specimens such as serum or plasma.
- Maximization of biomarker utility across healthy and diseased states.
- Measurement of minute changes in biomarker concentration, with the accuracy to establish velocity over a broad working range.
- Evaluation of therapeutic efficacy by comparing changes in biomarker levels in disease specimens to healthy, baseline levels.
- Analysis of therapeutic compound safety with respect to issues like cardiotoxicity across multiple animal models.
- Dosage optimization that balances efficacy with safety.
Singulex has a proven track record of achieving success with our ETAP partners. In the past year, we delivered
17 best-in-class assays that met or exceeded customer specifications for on-time delivery and performance with
100% success. Pilot studies with our ETAP partners and academic collaborators have led to peer-reviewed
publications in highly respected journals and presentations at scientific
meetings. Our ETAP partners
represent top-notch academic institutions and world renowned pharmaceutical partners.
|
